Quarterly ResultMay 14, 2026, 07:32 AM
CorMedix Q1 2026 Net Revenue $127.4M; Raises FY26 Guidance
AI Summary
CorMedix reported strong first quarter 2026 financial results, with net revenue of $127.4 million and net income of $38.6 million, significantly increasing from the prior year. The company also raised its full-year 2026 net revenue and adjusted EBITDA guidance, reflecting robust performance driven by DefenCath sales and contributions from the Melinta portfolio. Additionally, CorMedix announced positive Phase III topline results for REZZAYO and is advancing its pipeline, while maintaining a strong cash position.
Key Highlights
- CorMedix Q1 2026 net revenue was $127.4 million, up from $39.1 million in Q1 2025.
- Q1 2026 net income reached $38.6 million, compared to $20.6 million in Q1 2025.
- Adjusted EBITDA for Q1 2026 was $70.0 million, significantly up from $23.6 million in Q1 2025.
- DefenCath sales contributed $97.5 million to net revenue, including a $9.0 million favorable change in estimate.
- The acquired Melinta portfolio added $29.9 million in net revenue.
- Company raised full-year 2026 net revenue guidance to $325-$345 million.
- Full-year adjusted EBITDA guidance increased to $115-$135 million.
- Cash and short-term investments totaled $178.1 million at March 31, 2026.